South China Morning Post
Despite the broadened scope of CFIUS to review transactions, Morrison & Foerster partner Thomas T.H. Chou advised in the South China Morning Post article “Leading Chinese biotech firm Wuxi AppTec says US hurdles will not dim acquisition appetite” that Chinese firms are still actively seeking to make deals with U.S. companies.
“U.S. biotech companies generally remain quite interested in partnering with Chinese companies because of the enormous market potential and the recognition that the Chinese are increasingly innovative. That is why the industry trade groups are trying to find ways to help address U.S. national security concerns without cutting off the U.S. from the innovations that are occurring in China,” he said.